The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.